ArticleFrontiers in oncology2026
Case Report: Successful treatment of mixed-phenotype acute leukemia with cauda equina syndrome as the initial manifestation.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mixed-phenotype acute leukemia (MPAL) has a poor prognosis, and initial presentation with cauda equina syndrome (CES) is extremely rare. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) may be the only potentially curative modality. To our knowledge, this is the first reported case of MPAL presenting with CES at disease onset. Methods: We reviewed the clinical data of a 21-year-old man with high-risk myeloid/B-lymphoid MPAL presenting with CES as the initial manifestation. The patient initially presented with lumbosacral radicular pain and lower limb numbness, which rapidly progressed to fecal and urinary incontinence and inability to ambulate. Comprehensive imaging examinations and sacral biopsy ultimately confirmed myeloid/pre-B lymphoblastic MPAL with cauda equina and lumbosacral nerve root involvement. After the patient achieved complete remission with the combination chemotherapy regimen (MTRix + VD + BCL-2i), which features high blood-nerve-barrier penetration, the patient received myeloablative conditioning based on fractionated total-body irradiation and then underwent matched unrelated donor allo-HSCT. Third-party umbilical cord blood stem cells (UCBs) and mesenchymal stem cells (MSCs) were administered as adjunctive support. Graft-versus-host disease (GVHD) prophylaxis consisted of cyclosporine A, mycophenolate mofetil, and short-course methotrexate. Results: Neutrophil and platelet engraftment occurred on days +12 and +10 post-transplant, respectively. At the 24-month follow-up, the patient remained in minimal residual disease (MRD)-negative remission of the primary disease, free of acute and chronic GVHD, with motor strength recovery from grade 0 to grade 3. Conclusion: In conclusion, evidence-based multi-agent chemotherapy followed by allo-HSCT with third-party UCBs and MSC support resulted in favorable engraftment kinetics, adequate GVHD prophylaxis, and long-term remission. These outcomes support its clinical application. These findings highlight the promising efficacy and safety of this combined treatment approach in this high-risk MPAL case.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.